{ "data": [ { "id": "stat_MBM4FPC6Q63D53V4H7947N7R0N", "url": "https://statorigin.org/stat/stat_MBM4FPC6Q63D53V4H7947N7R0N", "indicator": { "slug": "approved-immunotherapy-drugs-multi-year-total", "name": "Approved immunotherapy drugs (multi-year total)", "definition": "Cumulative number of immunotherapy pharmaceutical products authorized for therapeutic use." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2010-01-01", "end": "2025-12-31", "type": "year" }, "value": 30, "value_text": "over 30", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "PhRMA", "org_short_name": "PhRMA", "org_url": "https://phrma.org", "org_tier": 2, "document_title": "Research & Development", "document_url": "https://phrma.org/policy-issues/research-development", "document_type": "press_release", "locator": "Revolutionizing Cancer Care with Immunotherapy", "quote": "Since 2010, over 30 immunotherapy drugs have been approved to treat 25 types of cancer.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_MBM4FPC6Q63D53V4H7947N7R0N", "bibtex": "@misc{phrma2025approved7n7r0n,\n author = {{PhRMA}},\n title = {Research \\& Development},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_MBM4FPC6Q63D53V4H7947N7R0N},\n note = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_AA927K4APEG4WA76H7YWADD4EW", "url": "https://statorigin.org/stat/stat_AA927K4APEG4WA76H7YWADD4EW", "indicator": { "slug": "biopharmaceutical-r-d-expenditure-multi-year-total", "name": "Biopharmaceutical R&D expenditure (multi-year total)", "definition": "Total capital expenditure invested by biopharmaceutical companies into research and development of new medicines." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2015-01-01", "end": "2024-12-31", "type": "year" }, "value": 900, "value_text": "over $900 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "PhRMA", "org_short_name": "PhRMA", "org_url": "https://phrma.org", "org_tier": 2, "document_title": "Research & Development", "document_url": "https://phrma.org/policy-issues/research-development", "document_type": "press_release", "locator": "Policy Framework", "quote": "Over the past decade, PhRMA member companies have invested over $900 billion in developing new treatments and cures, yielding groundbreaking results.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "PhRMA. (2024). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_AA927K4APEG4WA76H7YWADD4EW", "bibtex": "@misc{phrma2024biopharmaceuticaladd4ew,\n author = {{PhRMA}},\n title = {Research \\& Development},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_AA927K4APEG4WA76H7YWADD4EW},\n note = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_GJ0HSPRESAY30Y07N4XMBZF857", "url": "https://statorigin.org/stat/stat_GJ0HSPRESAY30Y07N4XMBZF857", "indicator": { "slug": "biosimilar-biological-product-approvals", "name": "Biosimilar biological product approvals", "definition": "Number of biosimilar biological products approved during the period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 18, "value_text": "18", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024", "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024", "document_type": "press_release", "locator": "A Record Year for Biosimilar Approvals", "quote": "This milestone is due to CDER approving in 2024 a record total of 18 biosimilars for 8 reference products, more than any previous year.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_GJ0HSPRESAY30Y07N4XMBZF857", "bibtex": "@misc{fda2024biosimilarbzf857,\n author = {{U.S. Food and Drug Administration}},\n title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_GJ0HSPRESAY30Y07N4XMBZF857},\n note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_NRSYQY2AXZDY94AMEFRD5DCGKY", "url": "https://statorigin.org/stat/stat_NRSYQY2AXZDY94AMEFRD5DCGKY", "indicator": { "slug": "botanical-drug-products-approved-as-prescription-drugs", "name": "Botanical drug products approved as prescription drugs", "definition": "Cumulative number of botanical drug products approved for marketing as prescription drugs through new drug applications." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-09-03", "end": "2026-09-03", "type": "point" }, "value": 4, "value_text": "four", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "FDA Seeks Public Input to Advance Development of Botanical Drug Products", "document_url": "https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products", "document_type": "press_release", "locator": "FDA Seeks Public Input to Advance Development of Botanical Drug Products", "quote": "To date, four botanical products have been approved for marketing as prescription drugs through the FDA’s new drug application and biologics license application pathways.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2026). FDA Seeks Public Input to Advance Development of Botanical Drug Products. Retrieved September 17, 2026, from https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products. Via StatOrigin, https://statorigin.org/stat/stat_NRSYQY2AXZDY94AMEFRD5DCGKY", "bibtex": "@misc{fda2026botanical5dcgky,\n author = {{U.S. Food and Drug Administration}},\n title = {FDA Seeks Public Input to Advance Development of Botanical Drug Products},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_NRSYQY2AXZDY94AMEFRD5DCGKY},\n note = {Original source: https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-advance-development-botanical-drug-products. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNA", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNA", "indicator": { "slug": "covid-19-vaccines-and-therapeutics-spending-decline", "name": "COVID-19 vaccines and therapeutics spending decline", "definition": "Annual decline in spending on COVID-19 vaccines and antiviral therapeutics." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 4, "value_text": "$4 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "COVID‑19 vaccines and therapeutics, which contributed to spending growth in 2024, declined by $4 billion in 2025.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNA", "bibtex": "@misc{iqvia2025covidkt7nna,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNA},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNX", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNX", "indicator": { "slug": "cell-and-gene-therapy-spending-share-by-geography", "name": "Cell and gene therapy spending share by geography", "definition": "Percentage of cell and gene therapy spending attributable to a given geography." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2023-01-01", "end": "2023-12-31", "type": "year" }, "value": 62, "value_text": "62%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies", "document_type": "press_release", "locator": "Global cell and gene therapy spending and share by geography", "quote": "A majority (62%) of this spending is attributable to U.S. sales, compared to just 38% coming from other geographies.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNX", "bibtex": "@misc{iqvia2023cellkt7nnx,\n author = {{IQVIA Institute}},\n title = {Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNX},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/strengthening-pathways-for-cell-and-gene-therapies. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_V2J1XACMRQE968NSWN5E8TT1Q5", "url": "https://statorigin.org/stat/stat_V2J1XACMRQE968NSWN5E8TT1Q5", "indicator": { "slug": "clinical-development-regulatory-approval-rate", "name": "Clinical development regulatory approval rate", "definition": "Proportion of drug candidates entering clinical trials that successfully receive regulatory marketing authorization." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "point" }, "value": 12, "value_text": "12%", "unit": "percent", "currency": null, "scale": "1", "value_type": "estimate", "source": { "org": "PhRMA", "org_short_name": "PhRMA", "org_url": "https://phrma.org", "org_tier": 2, "document_title": "Research & Development", "document_url": "https://phrma.org/policy-issues/research-development", "document_type": "press_release", "locator": "Progress toward New Medicines and Vaccines", "quote": "Only 12% of new molecular entities that enter clinical trials eventually receive U.S. Food and Drug Administration (FDA) approval.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_V2J1XACMRQE968NSWN5E8TT1Q5", "bibtex": "@misc{phrma2025clinical8tt1q5,\n author = {{PhRMA}},\n title = {Research \\& Development},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_V2J1XACMRQE968NSWN5E8TT1Q5},\n note = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCT", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCT", "indicator": { "slug": "clinical-trial-country-use-share", "name": "Clinical trial country use share", "definition": "Percentage of total clinical trial country uses accounted for by a given region." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2023-12-31", "type": "year" }, "value": 16, "value_text": "16%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Rethinking Clinical Trial Country Prioritization", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization", "document_type": "press_release", "locator": "Country utilization is heavily consolidated in U.S., China and Western European countries", "quote": "The top 10 most used countries account for 58% of the total average pipeline country use, with the United States and China responsible for 16% and 13%, respectively, of total country-uses for trials started in the 2021–2023 timeframe.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCT", "bibtex": "@misc{iqvia2023clinicalbjmgct,\n author = {{IQVIA Institute}},\n title = {Rethinking Clinical Trial Country Prioritization},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCT},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_H7DPFVJGXQAMKZ92F3CWG9K3Y4", "url": "https://statorigin.org/stat/stat_H7DPFVJGXQAMKZ92F3CWG9K3Y4", "indicator": { "slug": "commercial-insurance-patient-out-of-pocket-medicine-cost-growth-rate", "name": "Commercial insurance patient out-of-pocket medicine cost growth rate", "definition": "Annual percentage growth in aggregate out-of-pocket medicine spending for commercially insured patients." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 5, "value_text": "5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Commercial insurance out‑of‑pocket costs, which account for 52% of total patient out‑of‑pocket costs, rose 5% in aggregate in 2025 and 37% over five years due to increased volume and a shift towards higher‑cost prescriptions.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_H7DPFVJGXQAMKZ92F3CWG9K3Y4", "bibtex": "@misc{iqvia2025commercialg9k3y4,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_H7DPFVJGXQAMKZ92F3CWG9K3Y4},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_P27F75WTH77JYT1XF5RQ253JYM", "url": "https://statorigin.org/stat/stat_P27F75WTH77JYT1XF5RQ253JYM", "indicator": { "slug": "commercial-insurance-share-of-patient-out-of-pocket-medicine-costs", "name": "Commercial insurance share of patient out-of-pocket medicine costs", "definition": "Share of total patient out-of-pocket medicine costs accounted for by commercially insured patients." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 52, "value_text": "52%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Commercial insurance out‑of‑pocket costs, which account for 52% of total patient out‑of‑pocket costs, rose 5% in aggregate in 2025 and 37% over five years due to increased volume and a shift towards higher‑cost prescriptions.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_P27F75WTH77JYT1XF5RQ253JYM", "bibtex": "@misc{iqvia2025commercial253jym,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_P27F75WTH77JYT1XF5RQ253JYM},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_F34RHKHZS2FXGR5VF26CT43Z3Z", "url": "https://statorigin.org/stat/stat_F34RHKHZS2FXGR5VF26CT43Z3Z", "indicator": { "slug": "company-operating-locations", "name": "Company operating locations", "definition": "Total number of distinct operational locations maintained by a pharmaceutical company." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-08-20", "end": "2026-08-20", "type": "point" }, "value": 24, "value_text": "24", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "Roche", "org_short_name": "Roche", "org_url": "https://www.roche.com", "org_tier": 2, "document_title": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "document_url": "https://www.roche.com/media/releases/med-cor-2026-08-20", "document_type": "press_release", "locator": "Roche’s US subsidiary Genentech announces manufacturing expansion in the United States", "quote": "Roche and Genentech’s current U.S. footprint includes 13 manufacturing sites, 15 research and development sites and approximately 25,000 employees across 24 locations in eight states.", "published_date": "2026-08-20", "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "Roche. (2026). Roche’s US subsidiary Genentech announces manufacturing expansion in the United States. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-08-20. Via StatOrigin, https://statorigin.org/stat/stat_F34RHKHZS2FXGR5VF26CT43Z3Z", "bibtex": "@misc{roche2026companyt43z3z,\n author = {{Roche}},\n title = {Roche’s US subsidiary Genentech announces manufacturing expansion in the United States},\n year = {2026},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_F34RHKHZS2FXGR5VF26CT43Z3Z},\n note = {Original source: https://www.roche.com/media/releases/med-cor-2026-08-20. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NMX", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMX", "indicator": { "slug": "compound-annual-net-medicine-spending-growth", "name": "Compound annual net medicine spending growth", "definition": "Average annual growth rate of medicine spending at net prices over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2025-12-31", "type": "year" }, "value": 9.3, "value_text": "9.3%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "The U.S. market at net prices grew 10.6% in 2025 and an average of 9.3% annually over the last five years", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMX", "bibtex": "@misc{iqvia2025compoundkt7nmx,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMX},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_C9H3H7G4QK2418S8SH3H1NE64T", "url": "https://statorigin.org/stat/stat_C9H3H7G4QK2418S8SH3H1NE64T", "indicator": { "slug": "cumulative-biopharmaceutical-r-d-expenditure", "name": "Cumulative biopharmaceutical R&D expenditure", "definition": "Cumulative capital expenditure invested in biopharmaceutical research and development across member companies over a designated period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2000-01-01", "end": "2025-12-31", "type": "year" }, "value": 1, "value_text": "over $1 trillion dollars", "unit": "USD", "currency": "USD", "scale": "trillion", "value_type": "actual", "source": { "org": "PhRMA", "org_short_name": "PhRMA", "org_url": "https://phrma.org", "org_tier": 2, "document_title": "Research & Development", "document_url": "https://phrma.org/policy-issues/research-development", "document_type": "press_release", "locator": "Committed to Research", "quote": "PhRMA member companies have invested over $1 trillion dollars in R&D since 2000, establishing the biopharmaceutical sector as the most R&D-intensive industry in the U.S. economy.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "PhRMA. (2025). Research & Development. Retrieved September 17, 2026, from https://phrma.org/policy-issues/research-development. Via StatOrigin, https://statorigin.org/stat/stat_C9H3H7G4QK2418S8SH3H1NE64T", "bibtex": "@misc{phrma2025cumulative1ne64t,\n author = {{PhRMA}},\n title = {Research \\& Development},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_C9H3H7G4QK2418S8SH3H1NE64T},\n note = {Original source: https://phrma.org/policy-issues/research-development. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_92Y7GY7XN338491G60KZNPBNHR", "url": "https://statorigin.org/stat/stat_92Y7GY7XN338491G60KZNPBNHR", "indicator": { "slug": "cumulative-biosimilar-approvals", "name": "Cumulative biosimilar approvals", "definition": "Cumulative total number of biosimilar biological products approved since inception." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2015-01-01", "end": "2024-12-31", "type": "year" }, "value": 60, "value_text": "60th", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024", "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024", "document_type": "press_release", "locator": "A Record Year for Biosimilar Approvals", "quote": "CDER surpassed a major approval milestone for biosimilar biological products (biosimilars) in 2024 when it approved the 60th biosimilar since the first biosimilar approval in 2015.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_92Y7GY7XN338491G60KZNPBNHR", "bibtex": "@misc{fda2024cumulativenpbnhr,\n author = {{U.S. Food and Drug Administration}},\n title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_92Y7GY7XN338491G60KZNPBNHR},\n note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NPC", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPC", "indicator": { "slug": "cumulative-five-year-novel-active-substance-launches", "name": "Cumulative five-year novel active substance launches", "definition": "Total cumulative number of novel active substances launched over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 270, "value_text": "270", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "A total of 53 NAS launched in the U.S. in 2025, bringing the five-year total to 270.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPC", "bibtex": "@misc{iqvia2025cumulativekt7npc,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPC},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD7", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD7", "indicator": { "slug": "cumulative-five-year-novel-active-substance-launches", "name": "Cumulative five-year novel active substance launches", "definition": "Total cumulative number of novel active substances launched over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 270, "value_text": "270", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "A total of 53 NAS launched in the U.S. in 2025, bringing the five-year total to 270.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD7", "bibtex": "@misc{iqvia2025cumulativebjmgd7,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD7},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNB", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNB", "indicator": { "slug": "expected-annual-novel-active-substance-launches-lower-bound", "name": "Expected annual novel active substance launches (lower bound)", "definition": "Lower bound of the projected average annual number of novel active substance launches over the next five years." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 50, "value_text": "50", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Growth will be driven by the adoption of newly launched innovative products, with an average of 50–55 new medicines expected to launch annually over the next five years, including therapies in oncology, immunology, and other specialty areas, as well as more traditional treatments in diabetes, obesity, and neurology.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNB", "bibtex": "@misc{iqvia2030expectedkt7nnb,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNB},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NNC", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNC", "indicator": { "slug": "expected-annual-novel-active-substance-launches-upper-bound", "name": "Expected annual novel active substance launches (upper bound)", "definition": "Upper bound of the projected average annual number of novel active substance launches over the next five years." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 55, "value_text": "55", "unit": "count", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Growth will be driven by the adoption of newly launched innovative products, with an average of 50–55 new medicines expected to launch annually over the next five years, including therapies in oncology, immunology, and other specialty areas, as well as more traditional treatments in diabetes, obesity, and neurology.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNC", "bibtex": "@misc{iqvia2030expectedkt7nnc,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NNC},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_7HV4S9S7GYPN08FQAGH9VPCWB5", "url": "https://statorigin.org/stat/stat_7HV4S9S7GYPN08FQAGH9VPCWB5", "indicator": { "slug": "first-cycle-novel-drug-approvals", "name": "First-cycle novel drug approvals", "definition": "Number of novel drugs approved on the first regulatory review cycle." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 37, "value_text": "37", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024", "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024", "document_type": "press_release", "locator": "CDER’s Effectiveness Bringing New Therapies to Market", "quote": "First Cycle Approvals: 37 of the 50 novel drugs approved in 2024 (74%) were approved on the “first cycle” of review.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_7HV4S9S7GYPN08FQAGH9VPCWB5", "bibtex": "@misc{fda2024firstvpcwb5,\n author = {{U.S. Food and Drug Administration}},\n title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7HV4S9S7GYPN08FQAGH9VPCWB5},\n note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_JM2XHZ4K746FQVB9DGV1W2TYWT", "url": "https://statorigin.org/stat/stat_JM2XHZ4K746FQVB9DGV1W2TYWT", "indicator": { "slug": "first-year-new-prescriptions-for-novel-medicines-multi-year-total", "name": "First-year new prescriptions for novel medicines (multi-year total)", "definition": "Total volume of new prescriptions written during the first year of market availability for newly launched medicines." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 7, "value_text": "7 million", "unit": "count", "currency": null, "scale": "million", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "For these medicines, 7 million new prescriptions were written in the first year of availability, with 64% related to RSV vaccines alone.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_JM2XHZ4K746FQVB9DGV1W2TYWT", "bibtex": "@misc{iqvia2024firstw2tywt,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JM2XHZ4K746FQVB9DGV1W2TYWT},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_7Q206KR0B5YTYRQ523FNSCNP4R", "url": "https://statorigin.org/stat/stat_7Q206KR0B5YTYRQ523FNSCNP4R", "indicator": { "slug": "five-year-cumulative-medicine-use-growth", "name": "Five-year cumulative medicine use growth", "definition": "Cumulative percentage increase in prescription medicine use based on defined daily doses over a five-year period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2025-12-31", "type": "year" }, "value": 13, "value_text": "13%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "The use of prescription medicines in the U.S. — based on defined daily doses — has grown 13% in the last five years to 210 billion days of therapy across both retail and non‑retail settings, although growth slowed beginning in 2024.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_7Q206KR0B5YTYRQ523FNSCNP4R", "bibtex": "@misc{iqvia2025fivescnp4r,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_7Q206KR0B5YTYRQ523FNSCNP4R},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN0", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN0", "indicator": { "slug": "forecast-list-price-medicine-spending-growth-lower-bound", "name": "Forecast list-price medicine spending growth lower bound", "definition": "Projected lower-bound compound annual growth rate of medicine spending at list prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 6, "value_text": "6", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "U.S. medicine spending at net prices is forecast to grow 4.5 to 7.5% through 2030, while 6 to 9% at list prices", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN0", "bibtex": "@misc{iqvia2030forecastkt7nn0,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN0},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN1", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN1", "indicator": { "slug": "forecast-list-price-medicine-spending-growth-upper-bound", "name": "Forecast list-price medicine spending growth upper bound", "definition": "Projected upper-bound compound annual growth rate of medicine spending at list prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 9, "value_text": "9%", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "U.S. medicine spending at net prices is forecast to grow 4.5 to 7.5% through 2030, while 6 to 9% at list prices", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN1", "bibtex": "@misc{iqvia2030forecastkt7nn1,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN1},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NMY", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMY", "indicator": { "slug": "forecast-net-medicine-spending-growth-lower-bound", "name": "Forecast net medicine spending growth lower bound", "definition": "Projected lower-bound compound annual growth rate of medicine spending at net prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 4.5, "value_text": "4.5", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "U.S. medicine spending at net prices is forecast to grow 4.5 to 7.5% through 2030, while 6 to 9% at list prices", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMY", "bibtex": "@misc{iqvia2030forecastkt7nmy,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMY},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NMZ", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMZ", "indicator": { "slug": "forecast-net-medicine-spending-growth-upper-bound", "name": "Forecast net medicine spending growth upper bound", "definition": "Projected upper-bound compound annual growth rate of medicine spending at net prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2026-01-01", "end": "2030-12-31", "type": "year" }, "value": 7.5, "value_text": "7.5%", "unit": "percent", "currency": null, "scale": "1", "value_type": "forecast", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "U.S. medicine spending at net prices is forecast to grow 4.5 to 7.5% through 2030, while 6 to 9% at list prices", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2030). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMZ", "bibtex": "@misc{iqvia2030forecastkt7nmz,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2030},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMZ},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN9", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN9", "indicator": { "slug": "gip-glp-1-agonist-spending-growth-contribution", "name": "GIP/GLP-1 agonist spending growth contribution", "definition": "Annual monetary growth contributed by GIP/GLP-1 agonist medicines across diabetes and obesity indications." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 14, "value_text": "$14 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "GIP/GLP‑1 agonists across diabetes and obesity contributed $14 billion in growth, with $9.6 billion concentrated in products approved for obesity and related comorbidities.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN9", "bibtex": "@misc{iqvia2025agonistkt7nn9,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN9},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_T9AE55AFXEF16A7X4A2CB52TZF", "url": "https://statorigin.org/stat/stat_T9AE55AFXEF16A7X4A2CB52TZF", "indicator": { "slug": "health-sector-research-and-development-investment-growth-rate", "name": "Health sector research and development investment growth rate", "definition": "Annual percentage change in research and development investment by health sector companies." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 7.1, "value_text": "7.1%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "European Commission", "org_short_name": "European Commission", "org_url": "https://ec.europa.eu", "org_tier": 1, "document_title": "The 2025 EU Industrial R&D Investment Scoreboard", "document_url": "https://joint-research-centre.ec.europa.eu/jrc-news-and-updates/2025-eu-industrial-rd-investment-scoreboard-2025-12-22_en", "document_type": "press_release", "locator": "EU: Health and energy sectors shine in a year of slowdown", "quote": "EU companies in the health sector increased R&D investments by 13%, outperforming other regions such as the United States (7.1%), Japan (9.1%), and China (0.1%).", "published_date": "2025-12-22", "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "European Commission. (2025). The 2025 EU Industrial R&D Investment Scoreboard. Retrieved September 17, 2026, from https://joint-research-centre.ec.europa.eu/jrc-news-and-updates/2025-eu-industrial-rd-investment-scoreboard-2025-12-22_en. Via StatOrigin, https://statorigin.org/stat/stat_T9AE55AFXEF16A7X4A2CB52TZF", "bibtex": "@misc{europeancommissi2025healthb52tzf,\n author = {{European Commission}},\n title = {The 2025 EU Industrial R\\&D Investment Scoreboard},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_T9AE55AFXEF16A7X4A2CB52TZF},\n note = {Original source: https://joint-research-centre.ec.europa.eu/jrc-news-and-updates/2025-eu-industrial-rd-investment-scoreboard-2025-12-22\\_en. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_FGN4ATG2813DKK24SP6N6W5BDM", "url": "https://statorigin.org/stat/stat_FGN4ATG2813DKK24SP6N6W5BDM", "indicator": { "slug": "interchangeable-biosimilar-approvals", "name": "Interchangeable biosimilar approvals", "definition": "Number of interchangeable biosimilar biological products approved during the period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 9, "value_text": "9", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024", "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024", "document_type": "press_release", "locator": "A Record Year for Biosimilar Approvals", "quote": "Also in 2024, CDER approved 9 interchangeable biosimilars (for new and previously approved biosimilars).", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_FGN4ATG2813DKK24SP6N6W5BDM", "bibtex": "@misc{fda2024interchangeable6w5bdm,\n author = {{U.S. Food and Drug Administration}},\n title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_FGN4ATG2813DKK24SP6N6W5BDM},\n note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_8J3C6WP1FE8YZ13MEAG6AZNK1D", "url": "https://statorigin.org/stat/stat_8J3C6WP1FE8YZ13MEAG6AZNK1D", "indicator": { "slug": "life-sciences-and-patient-organization-deal-value", "name": "Life sciences and patient organization deal value", "definition": "Estimated total aggregate value of publicly announced deals between patient organizations and life sciences companies." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2008-01-01", "end": "2023-10-05", "type": "point" }, "value": 2.4, "value_text": "$2.4 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "estimate", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Supporting patients through research collaboration", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration", "document_type": "press_release", "locator": "Key findings:", "quote": "Nearly 700 deals with an estimated aggregate value of $2.4 billion have been publicly announced between patient organizations and life sciences companies over the past 15 years.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Supporting patients through research collaboration. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Via StatOrigin, https://statorigin.org/stat/stat_8J3C6WP1FE8YZ13MEAG6AZNK1D", "bibtex": "@misc{iqvia2023lifeaznk1d,\n author = {{IQVIA Institute}},\n title = {Supporting patients through research collaboration},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_8J3C6WP1FE8YZ13MEAG6AZNK1D},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_VMCR6QGZ4YDG5FFXQ3H2SKPE7C", "url": "https://statorigin.org/stat/stat_VMCR6QGZ4YDG5FFXQ3H2SKPE7C", "indicator": { "slug": "life-sciences-and-patient-organization-deals", "name": "Life sciences and patient organization deals", "definition": "Number of publicly announced deals between patient organizations and life sciences companies." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2008-01-01", "end": "2023-10-05", "type": "point" }, "value": 700, "value_text": "700", "unit": "count", "currency": null, "scale": "1", "value_type": "estimate", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Supporting patients through research collaboration", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration", "document_type": "press_release", "locator": "Key findings:", "quote": "Nearly 700 deals with an estimated aggregate value of $2.4 billion have been publicly announced between patient organizations and life sciences companies over the past 15 years.", "published_date": null, "accessed_at": "2026-09-16", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2023). Supporting patients through research collaboration. Retrieved September 16, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Via StatOrigin, https://statorigin.org/stat/stat_VMCR6QGZ4YDG5FFXQ3H2SKPE7C", "bibtex": "@misc{iqvia2023lifeskpe7c,\n author = {{IQVIA Institute}},\n title = {Supporting patients through research collaboration},\n year = {2023},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_VMCR6QGZ4YDG5FFXQ3H2SKPE7C},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/supporting-patients-through-research-collaboration. Accessed September 16, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_Y4MCHKK0581X3X5N369ZRY0DN7", "url": "https://statorigin.org/stat/stat_Y4MCHKK0581X3X5N369ZRY0DN7", "indicator": { "slug": "medicare-patient-out-of-pocket-medicine-cost-decline", "name": "Medicare patient out-of-pocket medicine cost decline", "definition": "Annual reduction in aggregate Medicare patient out-of-pocket medicine spending." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 638, "value_text": "$638 million", "unit": "USD", "currency": "USD", "scale": "million", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Medicare out‑of‑pocket costs declined by $638 million (2.2%) in aggregate in 2025 following the implementation of the Medicare Part D out‑of‑pocket cap; however, costs remain more than $5.3 billion (23%) higher than in 2020, driven by increased volume and shifts in prescription mix.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_Y4MCHKK0581X3X5N369ZRY0DN7", "bibtex": "@misc{iqvia2025medicarery0dn7,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_Y4MCHKK0581X3X5N369ZRY0DN7},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_K680H5ZG8Z65RQ9RNQQNXTXYS5", "url": "https://statorigin.org/stat/stat_K680H5ZG8Z65RQ9RNQQNXTXYS5", "indicator": { "slug": "medicare-patient-out-of-pocket-medicine-cost-decline-rate", "name": "Medicare patient out-of-pocket medicine cost decline rate", "definition": "Annual percentage decline in aggregate Medicare patient out-of-pocket medicine spending." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 2.2, "value_text": "2.2%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Medicare out‑of‑pocket costs declined by $638 million (2.2%) in aggregate in 2025 following the implementation of the Medicare Part D out‑of‑pocket cap; however, costs remain more than $5.3 billion (23%) higher than in 2020, driven by increased volume and shifts in prescription mix.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_K680H5ZG8Z65RQ9RNQQNXTXYS5", "bibtex": "@misc{iqvia2025medicarextxys5,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_K680H5ZG8Z65RQ9RNQQNXTXYS5},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN8", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN8", "indicator": { "slug": "net-medicine-spending", "name": "Net medicine spending", "definition": "Total prescription medicine spending evaluated at net manufacturer prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 606, "value_text": "$606 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Net medicine spending increased by $58 billion (10.6%) in aggregate, rising from $548 billion in 2024 to $606 billion in 2025, with most growth driven by protected brands outside GIP/GLP‑1 agonists and COVID‑19 vaccines and therapeutics.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN8", "bibtex": "@misc{iqvia2025medicinekt7nn8,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN8},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN7", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN7", "indicator": { "slug": "net-medicine-spending", "name": "Net medicine spending", "definition": "Total prescription medicine spending evaluated at net manufacturer prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 548, "value_text": "$548 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Net medicine spending increased by $58 billion (10.6%) in aggregate, rising from $548 billion in 2024 to $606 billion in 2025, with most growth driven by protected brands outside GIP/GLP‑1 agonists and COVID‑19 vaccines and therapeutics.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN7", "bibtex": "@misc{iqvia2024medicinekt7nn7,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN7},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NMW", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMW", "indicator": { "slug": "net-medicine-spending-growth", "name": "Net medicine spending growth", "definition": "Annual growth rate of medicine spending evaluated at net manufacturer prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 10.6, "value_text": "10.6%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Key Findings", "quote": "The U.S. market at net prices grew 10.6% in 2025 and an average of 9.3% annually over the last five years", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMW", "bibtex": "@misc{iqvia2025medicinekt7nmw,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NMW},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN6", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN6", "indicator": { "slug": "net-medicine-spending-increase", "name": "Net medicine spending increase", "definition": "Annual absolute increase in total medicine spending evaluated at net manufacturer prices." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 58, "value_text": "$58 billion", "unit": "USD", "currency": "USD", "scale": "billion", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Net medicine spending increased by $58 billion (10.6%) in aggregate, rising from $548 billion in 2024 to $606 billion in 2025, with most growth driven by protected brands outside GIP/GLP‑1 agonists and COVID‑19 vaccines and therapeutics.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN6", "bibtex": "@misc{iqvia2025medicinekt7nn6,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN6},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NN3", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN3", "indicator": { "slug": "non-retail-share-of-prescription-medicine-use", "name": "Non-retail share of prescription medicine use", "definition": "Percentage share of total prescription medicine use accounted for by non-retail settings." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 16, "value_text": "16%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Retail drugs currently represent 84% of medicine use in the U.S., with only 16% in non‑retail settings, and non‑retail growth exceeded retail growth in 2025.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN3", "bibtex": "@misc{iqvia2025retailkt7nn3,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NN3},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NPB", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPB", "indicator": { "slug": "novel-active-substance-launches", "name": "Novel active substance launches", "definition": "Total number of novel active substances launched." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 53, "value_text": "53", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "A total of 53 NAS launched in the U.S. in 2025, bringing the five-year total to 270.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPB", "bibtex": "@misc{iqvia2025novelkt7npb,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPB},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD6", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD6", "indicator": { "slug": "novel-active-substance-launches", "name": "Novel active substance launches", "definition": "Total number of novel active substances launched." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true }, { "slug": "healthcare", "name": "Human health activities", "isic": "Q86", "is_primary": false } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 53, "value_text": "53", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "A total of 53 NAS launched in the U.S. in 2025, bringing the five-year total to 270.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD6", "bibtex": "@misc{iqvia2025novelbjmgd6,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD6},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_XY8VR1DEYCF7S3AY0BGJ8CBJSZ", "url": "https://statorigin.org/stat/stat_XY8VR1DEYCF7S3AY0BGJ8CBJSZ", "indicator": { "slug": "novel-active-substance-launches-multi-year-total", "name": "Novel active substance launches (multi-year total)", "definition": "Total number of novel active substances launched onto the market." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 270, "value_text": "270", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "A total of 53 NAS launched in the U.S. in 2025, bringing the five-year total to 270. This represents a 17% increase in the number of launches between 2021", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_XY8VR1DEYCF7S3AY0BGJ8CBJSZ", "bibtex": "@misc{iqvia2025novel8cbjsz,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_XY8VR1DEYCF7S3AY0BGJ8CBJSZ},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_D4PHY8WCXQVA15CJ4BD89BYBV0", "url": "https://statorigin.org/stat/stat_D4PHY8WCXQVA15CJ4BD89BYBV0", "indicator": { "slug": "novel-active-substance-launches-multi-year-total", "name": "Novel active substance launches (multi-year total)", "definition": "Total number of novel active substances launched onto the market." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2020-01-01", "end": "2024-12-31", "type": "year" }, "value": 99, "value_text": "99", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "U.S. Medicine Use Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026", "document_type": "press_release", "locator": "Other Findings", "quote": "Between 2020 and 2024, 99 novel medicines launched in retail and mail channels in the U.S., often providing benefits over standard of care or addressing unmet needs.", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2024). U.S. Medicine Use Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_D4PHY8WCXQVA15CJ4BD89BYBV0", "bibtex": "@misc{iqvia2024novel9bybv0,\n author = {{IQVIA Institute}},\n title = {U.S. Medicine Use Trends 2026},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_D4PHY8WCXQVA15CJ4BD89BYBV0},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_01M2KJ7XCF5037JCNPDKKT7NPD", "url": "https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPD", "indicator": { "slug": "novel-active-substance-launches-growth-rate", "name": "Novel active substance launches growth rate", "definition": "Percentage growth in novel active substance launches." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 17, "value_text": "17%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "This represents a 17% increase in the number of launches between 2021", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPD", "bibtex": "@misc{iqvia2025novelkt7npd,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCF5037JCNPDKKT7NPD},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGD8", "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD8", "indicator": { "slug": "novel-active-substance-launches-growth-rate", "name": "Novel active substance launches growth rate", "definition": "Percentage growth in novel active substance launches." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2021-01-01", "end": "2025-12-31", "type": "year" }, "value": 17, "value_text": "17%", "unit": "percent", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "IQVIA Institute", "org_short_name": "IQVIA", "org_url": "https://www.iqvia.com", "org_tier": 3, "document_title": "Global R&D Trends 2026", "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026", "document_type": "press_release", "locator": "Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025", "quote": "This represents a 17% increase in the number of launches between 2021", "published_date": null, "accessed_at": "2026-09-15", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-15T22:15:46.809Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD8", "bibtex": "@misc{iqvia2025novelbjmgd8,\n author = {{IQVIA Institute}},\n title = {Global R\\&D Trends 2026},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGD8},\n note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.}\n}" }, "updated_at": "2026-09-15T22:15:46.809Z" }, { "id": "stat_DTVZ86ZKKFMY4BRZGE6MNCJGKA", "url": "https://statorigin.org/stat/stat_DTVZ86ZKKFMY4BRZGE6MNCJGKA", "indicator": { "slug": "novel-antibiotic-approvals", "name": "Novel antibiotic approvals", "definition": "Number of new antibiotic therapies approved by regulatory authorities during the period." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 3, "value_text": "three", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024", "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024", "document_type": "press_release", "locator": "Creating a Yearly Snapshot for Approvals", "quote": "The 2024 report includes approvals for therapies that collectively treat a wide range of conditions, including a first-in-class drug for schizophrenia, three novel antibiotics and new drugs for many types of cancer.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_DTVZ86ZKKFMY4BRZGE6MNCJGKA", "bibtex": "@misc{fda2024novelncjgka,\n author = {{U.S. Food and Drug Administration}},\n title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_DTVZ86ZKKFMY4BRZGE6MNCJGKA},\n note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_FYPH5BNZDF28G5Z8B3HWEGC64Z", "url": "https://statorigin.org/stat/stat_FYPH5BNZDF28G5Z8B3HWEGC64Z", "indicator": { "slug": "novel-drug-approvals", "name": "Novel drug approvals", "definition": "Total number of novel drugs approved for the first time by a regulatory authority within a calendar year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2025-01-01", "end": "2025-12-31", "type": "year" }, "value": 46, "value_text": "46", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "Novel Drug Approvals for 2025", "document_url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025", "document_type": "press_release", "locator": "FDA Novel Drug Therapy Approvals for 2025", "quote": "In 2025, CDER approved 46 new drugs never before approved or marketed in the U.S., known as “novel” drugs.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2025). Novel Drug Approvals for 2025. Retrieved September 17, 2026, from https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025. Via StatOrigin, https://statorigin.org/stat/stat_FYPH5BNZDF28G5Z8B3HWEGC64Z", "bibtex": "@misc{fda2025novelegc64z,\n author = {{U.S. Food and Drug Administration}},\n title = {Novel Drug Approvals for 2025},\n year = {2025},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_FYPH5BNZDF28G5Z8B3HWEGC64Z},\n note = {Original source: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_YPEXVA6CNFQ4Q0A2YJX9PFV0GE", "url": "https://statorigin.org/stat/stat_YPEXVA6CNFQ4Q0A2YJX9PFV0GE", "indicator": { "slug": "novel-drug-approvals", "name": "Novel drug approvals", "definition": "Total number of novel drugs approved for the first time by a regulatory authority within a calendar year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 50, "value_text": "50", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "Novel Drug Approvals for 2024", "document_url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024", "document_type": "press_release", "locator": "FDA Novel Drug Therapy Approvals for 2024", "quote": "In 2024, CDER approved 50 new drugs never before approved or marketed in the U.S., known as “novel” drugs.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). Novel Drug Approvals for 2024. Retrieved September 17, 2026, from https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024. Via StatOrigin, https://statorigin.org/stat/stat_YPEXVA6CNFQ4Q0A2YJX9PFV0GE", "bibtex": "@misc{fda2024novelpfv0ge,\n author = {{U.S. Food and Drug Administration}},\n title = {Novel Drug Approvals for 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_YPEXVA6CNFQ4Q0A2YJX9PFV0GE},\n note = {Original source: https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_490P1RBES11QSCWQYHPQ8YMMZH", "url": "https://statorigin.org/stat/stat_490P1RBES11QSCWQYHPQ8YMMZH", "indicator": { "slug": "novel-drug-approvals", "name": "Novel drug approvals", "definition": "Total number of novel drugs approved for the first time by a regulatory authority within a calendar year." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 50, "value_text": "50", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024", "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024", "document_type": "press_release", "locator": "New Rare Disease Therapies in 2024", "quote": "In 2024, CDER approved 50 new drugs that had active ingredients not previously approved by the FDA.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_490P1RBES11QSCWQYHPQ8YMMZH", "bibtex": "@misc{fda2024novel8ymmzh,\n author = {{U.S. Food and Drug Administration}},\n title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_490P1RBES11QSCWQYHPQ8YMMZH},\n note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_JNK8ARWY2PGWWRZKZ7HYNGAPKT", "url": "https://statorigin.org/stat/stat_JNK8ARWY2PGWWRZKZ7HYNGAPKT", "indicator": { "slug": "novel-drug-approvals-meeting-user-fee-goal-dates", "name": "Novel drug approvals meeting user fee goal dates", "definition": "Number of novel drug approvals concluded within standard statutory or user fee review timelines." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 47, "value_text": "47", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024", "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024", "document_type": "press_release", "locator": "CDER’s Effectiveness Bringing New Therapies to Market", "quote": "User Fee Goal Performance: In 2024, CDER met or exceeded its Prescription Drug User Fee Act goal date for 47 of the 50 novel drug approvals (94%).", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_JNK8ARWY2PGWWRZKZ7HYNGAPKT", "bibtex": "@misc{fda2024novelngapkt,\n author = {{U.S. Food and Drug Administration}},\n title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_JNK8ARWY2PGWWRZKZ7HYNGAPKT},\n note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_E42Q7GDFNTTE16PB42TN238EC2", "url": "https://statorigin.org/stat/stat_E42Q7GDFNTTE16PB42TN238EC2", "indicator": { "slug": "novel-drug-approvals-using-expedited-programs", "name": "Novel drug approvals using expedited programs", "definition": "Number of novel therapies approved through one or more expedited regulatory review pathways." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 33, "value_text": "33", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024", "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024", "document_type": "press_release", "locator": "CDER’s Effectiveness Bringing New Therapies to Market", "quote": "Expedited Programs: In 2024, CDER approved 33 of the 50 new therapies (66%) using one or more expedited approval programs: fast track designation, breakthrough therapy designation, priority review designation, and Accelerated Approval.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_E42Q7GDFNTTE16PB42TN238EC2", "bibtex": "@misc{fda2024novel238ec2,\n author = {{U.S. Food and Drug Administration}},\n title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_E42Q7GDFNTTE16PB42TN238EC2},\n note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" }, { "id": "stat_QTAGJ6V8283NFRV6FMA50ER0VJ", "url": "https://statorigin.org/stat/stat_QTAGJ6V8283NFRV6FMA50ER0VJ", "indicator": { "slug": "novel-drugs-approved-first-in-domestic-market", "name": "Novel drugs approved first in domestic market", "definition": "Number of novel drugs approved in the reporting jurisdiction prior to receiving approval in other jurisdictions." }, "industry": [ { "slug": "pharmaceuticals", "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations", "isic": "C21", "is_primary": true } ], "region": { "code": "US", "name": "United States", "type": "country" }, "period": { "start": "2024-01-01", "end": "2024-12-31", "type": "year" }, "value": 34, "value_text": "34", "unit": "count", "currency": null, "scale": "1", "value_type": "actual", "source": { "org": "U.S. Food and Drug Administration", "org_short_name": "FDA", "org_url": "https://www.fda.gov", "org_tier": 1, "document_title": "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024", "document_url": "https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024", "document_type": "press_release", "locator": "CDER’s Effectiveness Bringing New Therapies to Market", "quote": "Approval in the U.S. Before Other Countries: In 2024, 34 of the 50 novel drugs approved by CDER (68%) were approved in the U.S. before being approved in other countries.", "published_date": null, "accessed_at": "2026-09-17", "license": "see-source", "url_status": "ok" }, "verification": "verified", "verified_by": "seed:auto-extract-v1", "verified_at": "2026-09-17T07:16:01.811Z", "confidence": 0.9, "is_secondhand": false, "supersedes": null, "superseded_by": null, "is_current": true, "citation": { "apa": "U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_QTAGJ6V8283NFRV6FMA50ER0VJ", "bibtex": "@misc{fda2024novel0er0vj,\n author = {{U.S. Food and Drug Administration}},\n title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024},\n year = {2024},\n howpublished = {StatOrigin, https://statorigin.org},\n url = {https://statorigin.org/stat/stat_QTAGJ6V8283NFRV6FMA50ER0VJ},\n note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.}\n}" }, "updated_at": "2026-09-17T07:16:01.811Z" } ], "meta": { "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.", "license": "https://creativecommons.org/licenses/by/4.0/", "docs": "https://statorigin.org/docs/api", "total": 90, "limit": 50, "next_cursor": "eyJvIjo1MH0=" } }